Antihypertensive Medications and Risk of Melanoma and Keratinocyte Carcinomas: A Systematic Review and Meta-Analysis.

Autor:	Cohen OG; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Taylor M; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Mohr C; Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Nead KT; Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hinkston CL; Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Giordano SH; Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Langan SM; Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom., Margolis DJ; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Wehner MR; Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jazyk:	angličtina
Zdroj:	JID innovations : skin science from molecules to population health [JID Innov] 2024 Mar 23; Vol. 4 (3), pp. 100272. Date of Electronic Publication: 2024 Mar 23 (Print Publication: 2024).
DOI:	10.1016/j.xjidi.2024.100272
Abstrakt:	Some antihypertensive medications are photosensitizing. The implications for skin cancer risk remain unclear because results from prior studies are inconsistent and as new evidence is published. We performed a systematic review and meta-analysis to evaluate the association between antihypertensives and common skin cancers (cutaneous squamous cell carcinoma, basal cell carcinoma, and melanoma) and to evaluate dose-response relationships. Forty-four articles met inclusion criteria, and 42 could be meta analyzed. Increased risks were seen for basal cell carcinoma with calcium channel blockers (relative risk [RR] = 1.17, 95% confidence interval [CI] = 1.11-1.22), diuretics (RR = 1.06, 95% CI = 1.03-1.10), and thiazides (RR = 1.10, 95% CI = 1.04-1.16); for squamous cell carcinoma with calcium channel blockers (RR = 1.08, 95% CI = 1.01-1.14), diuretics (RR = 1.29, 95% CI = 1.17-1.43), and thiazides (RR = 1.36, 95% CI = 1.15-1.61); and for melanoma in angiotensin-converting enzyme inhibitors (RR = 1.09, 95% CI = 1.03-1.14), calcium channel blockers (RR = 1.08, 95% CI = 1.03-1.12), and thiazides (RR = 1.09, 95% CI = 1.02-1.17). The quality of evidence was low or very low. We observed evidence for dose-response for thiazides with basal cell carcinoma; angiotensin-converting enzyme inhibitors, diuretics, and thiazides with squamous cell carcinoma; and angiotensin-converting enzyme inhibitors, diuretics, and thiazides with melanoma. Our meta-analysis supports a potential causal association between some antihypertensives, particularly diuretics, and skin cancer risk. (© 2024 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu